Investor's Business Daily on MSN
This biotech stock eyes fresh entry with 522% earnings growth seen
Medicine remains one of the most potentially rewarding of all investment areas. And this biotech stock is flirting with a buy ...
A run-up in biotech and drug stocks that sent valuations soaring through the second half of 2025 was looking a bit shaky on ...
Zacks.com on MSN
3 Biotech Stocks With Major 2026 Catalysts
Biotech's 2025 rebound sets the stage for Denali Therapeutics and two peers, with key FDA decisions and pipeline catalysts ...
24/7 Wall St. on MSN
Biotech Could Be One of 2026’s Biggest Winners, and This ETF Is Perfectly Positioned
Biotech investors spent years waiting for the sector to recover from its brutal 2021 peak. That patience is finally paying ...
Over the past few years, Axsome Therapeutics has made slow and steady clinical and regulatory progress. The company's lineup ...
O4, Jared Holz of Mizuho joined ‘Power Lunch’ on CNBC to talk about how to play biotech moving into 2026. Holz noted that ...
With partner Eli Lilly’s help, the radiopharmaceutical drugmaker priced one of the sector’s largest new stock offerings in ...
The Wall Street Journal report added that Revolution Medicines would bolster AbbVie's efforts to build its presence in the ...
A phase 3 study of Zenas BioPharma's autoimmune disease candidate has hit its primary endpoint. But, with the result falling ...
On the final trading day of 2025, Cathie Wood put an eye-brow raising $1.33 million to work in Intellia Therapeutics ( NTLA ) ...
By ending its agreement with ImmuneOnco, Instil is also handing back the other asset from the licensing deal: IMM27M, a next-gen anti-CTLA-4 antibody that ImmuneOnco had taken into phase 1 trials as a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback